China
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
Sponsored
Sponsored
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes -
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
-
Sponsored by Tahota Law FirmIn the first article of a two-part series, Charles Feng, Lian Xue, and Runjing Wang of Tahota Law Firm consider the different perspectives on whether China’s Anti-Unfair Competition Law should regulate internet advertising blocking
-
Sponsored by Tahota Law FirmA two-part series concludes with Charles Feng, Lian Xue, and Runjing Wang of Tahota Law Firm analysing relevant Chinese case law in assessing whether the mobile application LiTiaotiao constitutes unfair competition
-
Sponsored by Liu, Shen & AssociatesXuelan Yue of Liu Shen & Associates draws on several ‘model cases’ put forward by the Intellectual Property Court of the Supreme People’s Court of China to highlight trends in trade secret infringement cases
-
Sponsored by Wanhuida Intellectual PropertyA ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property
